Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy

Yanyan Peng, Deepali N. Shinde, C. Alexander Valencia, Jun Song Mo, Jill Rosenfeld, Megan Truitt Cho, Adam Chamberlin, Zhuo Li, Jie Liu, Baoheng Gui, Rachel Brockhage, Alice Basinger, Brenda Alvarez-Leon, Peter Heydemann, Pilar L. Magoulas, Andrea M. Lewis, Fernando Scaglia, Solange Gril, Shuk Ching Chong, Matthew BowerKristin G. Monaghan, Rebecca Willaert, Maria Renee Plona, Rich Dineen, Francisca Milan, George Hoganson, Zoe Powis, Katherine L. Helbig, Jennifer Keller-Ramey, Belinda Harris, Laura C. Anderson, Torrian Green, Stacey J. Sukoff Rizzo, Julie Kaylor, Jiani Chen, Min Xin Guan, Elizabeth Sellars, Steven P. Sparagana, James B. Gibson, Laura G. Reinholdt, Sha Tang, Taosheng Huang

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Iron-sulfur (Fe-S) clusters are ubiquitous cofactors essential to various cellular processes, including mitochondrial respiration, DNA repair, and iron homeostasis. A steadily increasing number of disorders are being associated with disrupted biogenesis of Fe-S clusters. Here, we conducted whole-exome sequencing of patients with optic atrophy and other neurological signs of mitochondriopathy and identified 17 individuals from 13 unrelated families with recessive mutations in FDXR, encoding the mitochondrial membrane-associated flavoprotein ferrodoxin reductase required for electron transport from NADPH to cytochrome P450. In vitro enzymatic assays in patient fibroblast cells showed deficient ferredoxin NADP reductase activity and mitochondrial dysfunction evidenced by low oxygen consumption rates (OCRs), complex activities, ATP production and increased reactive oxygen species (ROS). Such defects were rescued by overexpression of wild-type FDXR. Moreover, we found that mice carrying a spontaneous mutation allelic to the most common mutation found in patients displayed progressive gait abnormalities and vision loss, in addition to biochemical defects consistent with the major clinical features of the disease. Taken together, these data provide the first demonstration that germline, hypomorphic mutations in FDXR cause a novel mitochondriopathy and optic atrophy in humans.

Original languageEnglish (US)
Pages (from-to)4937-4950
Number of pages14
JournalHuman Molecular Genetics
Volume26
Issue number24
DOIs
StatePublished - Dec 1 2017

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy'. Together they form a unique fingerprint.

  • Cite this

    Peng, Y., Shinde, D. N., Valencia, C. A., Mo, J. S., Rosenfeld, J., Cho, M. T., Chamberlin, A., Li, Z., Liu, J., Gui, B., Brockhage, R., Basinger, A., Alvarez-Leon, B., Heydemann, P., Magoulas, P. L., Lewis, A. M., Scaglia, F., Gril, S., Chong, S. C., ... Huang, T. (2017). Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy. Human Molecular Genetics, 26(24), 4937-4950. https://doi.org/10.1093/hmg/ddx377